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Abstract
Background: Poor control of blood glucose in diabetes is known to promote vascular dysfunction
and hypertension. Diabetes was recently shown to be linked to an increased prevalence of
pulmonary hypertension. The aim of this study was to determine how the pharmacological
reactivity of intrapulmonary arteries is altered in a rat model of diabetes.
Methods: Diabetes was induced in rats by the β-cell toxin, streptozotocin (STZ, 60 mg/kg), and
isolated conduit and resistance intrapulmonary arteries studied 3–4 months later. Isometric tension
responses to the vasoconstrictors phenylephrine, serotonin and PGF2α, and the vasodilators
carbachol and glyceryl trinitrate, were compared in STZ-treated rats and age-matched controls.
Results: STZ-induced diabetes significantly blunted the maximum response of conduit, but not
resistance pulmonary arteries to phenylephrine and serotonin, without a change in pEC50. Agonist
responses were differentially reduced, with serotonin (46% smaller) affected more than
phenylephrine (32% smaller) and responses to PGF2α unaltered. Vasoconstriction caused by K+-
induced depolarisation remained normal in diabetic rats. Endothelium-dependent dilation to
carbachol and endothelium-independent dilation to glyceryl trinitrate were also unaffected.
Conclusion: The small resistance pulmonary arteries are relatively resistant to STZ-induced
diabetes. The impaired constrictor responsiveness of conduit vessels was agonist dependent,
suggesting possible loss of receptor expression or function. The observed effects cannot account
for pulmonary hypertension in diabetes, rather the impaired reactivity to vasoconstrictors would
counteract the development of pulmonary hypertensive disease.
Background
Hypertension is a recognised consequence of the poor
control of blood glucose in diabetes. A recent study found
that patients with diabetes mellitus also have an increased
prevalence of pulmonary hypertension, independent of
systemic hypertension, coronary artery disease, congestive
heart failure or smoking [1]. In addition, pulmonary
hypertension is more severe in patients with chronic
obstructive pulmonary disease if they also have diabetes
[2]. Furthermore, maternal diabetes is a risk factor for per-
sistent pulmonary hypertension of the newborn [3]. Thus
uncontrolled diabetes is a contributor to the development
of pulmonary vascular disease.
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The underlying cause of systemic hypertension in diabetes
is thought to be peripheral vasoconstriction [4] mediated,
at least in part, by endothelial dysfunction [5,6] and
enhanced smooth muscle contractility [7]. Little is known
about the cause of pulmonary hypertension, but there is
evidence from a rat model of diabetes, induced by strep-
tozotocin (STZ) [8], that uncontrolled plasma glucose
gives rise to structural [9] and biochemical [10] changes in
pulmonary arteries. A study of salt-perfused rat lungs
found that pulmonary vascular resistance was elevated in
male, but not female rats subject to STZ-induced diabetes,
along with reduced reactivity of the pulmonary vessels to
vasoconstrictors [11]. A recent report suggests that, as in
systemic vessels, STZ-induced diabetes in rats leads to loss
of endothelium-dependent relaxation in the main
intrapulmonary artery, possibly reflecting enhanced
superoxide production from NADPH oxidase [12].
A single injection of STZ is widely used to generate a rat
model of type I diabetes, which results from the selective
toxicity of STZ towards the insulin-producing β-cells in
pancreatic islets [13]. A number of factors influence the
vascular dysfunction that develops in this model, such as
the age of the rats, the dose of STZ administered and the
duration and severity of hyperglycaemia [8]. For example,
the endothelium-dependent relaxation of rat aorta was
enhanced 24 hrs after STZ injection, normal at 1–2 weeks
and depressed at 8 weeks [6]. Impaired endothelial func-
tion was also more common in young adult humans with
a longer duration of diabetes [14]. There may also be dif-
ferential effects of diabetes on different blood vessels. For
example, mesenteric arteries from STZ-treated rats dis-
played an enhanced vasoconstrictor response to
noradrenaline and reduced sensitivity to endothelium-
dependent vasodilators at a time (2–10 weeks after STZ
injection) when aortae from the same animals responded
normally [15].
Since the small resistance arteries in the lung are the main
determinants of pulmonary vascular resistance and pul-
monary arterial pressure, the aim of this study was to
determine how chronic diabetes (3–4 months) affects
these vessels. Reactivity to vasoconstrictors and vasodila-
tors was investigated in intrapulmonary arteries (IPA) of
≤250 μm in diameter and compared with larger conduit
arteries from the same lungs, in STZ diabetic animals and
age-matched controls.
Methods
Diabetes was induced in young male Wistar rats (200–250
g) by a single intraperitoneal injection of 60 mg/kg STZ
(Sigma) dissolved in citrate buffer, containing 100 mM
citric acid and 100 mM sodium citrate at pH 4.5. This dose
of STZ lies within the range used in most cardiovascular
studies and produces moderate diabetes, in which blood
glucose levels are 3–4 times normal, by causing substan-
tial but incomplete depletion of pancreatic insulin [16].
Age-matched controls received an equivalent volume of
vehicle. Control and STZ-treated animals were main-
tained on the same diet with freely available water. Ani-
mals were sacrificed at 3–4 months immediately after
measuring body weight and blood glucose. A blood glu-
cose level exceeding 200 mg/dL was considered diabetic.
The lungs were quickly removed into physiological salt
solution (PSS) of the following composition (mM): NaCl
112, KCl 5, KH2PO4 0.5, Na2HPO4 0.5, CaCl2 1.8, MgCl2
1, HEPES 10, glucose 11; pH7.3.
The investigation was approved by the ethics committee
of the Faculty of Medicine & Health Sciences, United Arab
Emirates University and conforms to the Guide for the
Care and Use of Laboratory Animals published by the
National Institutes of Health (NIH Publication No. 85-23,
revised 1996).
Small vessel myography
A section of conduit artery (~500 μm diameter), from half
way down the main artery running the length of the left
lung lobe, was dissected out and mounted between two
pins in a small vessel myograph chamber (Danish Myo-
technology). Resistance-sized intrapulmonary arteries (<
250 μm diameter) were dissected from the same lobe and
mounted between two 40 μm wires in separate myograph
chambers. The vessels were bathed in PSS continually aer-
ated at 37°C. A basal tension of 5 mN (conduit vessels) or
4 mN (resistance vessels) was applied and the vessels
allowed to equilibrate for 30 min, washing at 15 min
intervals. At the start of each experiment, 50 mM KCl was
applied to each vessel until a maximal contractile
response was observed. The vessels were then washed
until tension returned to baseline and the challenge with
high K+  repeated until reproducible contractions were
recorded.
The sensitivity of intrapulmonary arteries to depolarisa-
tion-induced constriction was determined by replacing
the PSS in the myograph chamber with PSS in which the
K+ concentration was sequentially increased to 15 mM, 30
mM, 50 mM, 70 mM, 90 mM or 110 mM, by equimolar
substitution of KCl for NaCl. To determine sensitivity to
vasoconstrictors, vessels were exposed to increasing con-
centrations of phenylephrine (0.1 nM – 100 μM), serot-
onin (1 nM – 100 μM) or prostaglandin F2α (PGF2α; 1 nM
– 10 μM), applied cumulatively with at least 5 min
between additions. The contractile force generated by the
different constrictor agents was measured as a percentage
of the force generated by 50 mM KCl, which evoked a
maximum contractile response of 2.1 ± 0.2 mN (n = 21)
and 2.8 ± 0.3 mN (n = 25) in large arteries from control
and STZ-treated animals, respectively, compared with 4.0Cardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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± 0.5 mN (n = 23) and 5.1 ± 0.9 mN (n = 23) in the small
arteries from control and STZ-treated animals. The maxi-
mum response and the concentration of drug causing
50% of the maximum response (EC50) were determined
by fitting the Hill equation to the dose-response curves for
each vessel.
To determine the sensitivity of intrapulmonary arteries to
vasodilator drugs, vessels were pre-constricted to near the
maximum response with a vasoconstrictor. Once a pla-
teau level of tension was reached, increasing concentra-
tions of carbachol (1 nM – 100 μM) or glyceryl trinitrate
(GTN; 1 nM – 100 μM) were applied cumulatively, with
at least 5 min between additions. Phenylephrine (100 nM
or 1 μM) was used as the vasoconstrictor for conduit ves-
sels. Resistance vessels showed small and variable
responses to phenylephrine, and agonist-induced con-
striction was not always sustained sufficiently to allow
dilator effects to be assessed. Individual resistance vessels
were therefore pre-constricted with whichever agent was
found to cause the most substantial and sustained con-
striction.
Data Analysis
Results are presented as mean ± S.E.M, with 'n' referring to
the number of rats used. Statistical analysis was performed
using Origin 7.5 (Origin Lab) or Excel 2003 (Microsoft)
software. A paired t-test was used to compare parameters
in conduit and resistance arteries from the same animals.
Otherwise an independent t-test was used for statistical
comparisons. P < 0.05 was taken to indicate significance.
Drugs
Glyceryl trinitrate (nitrocine) was obtained from Schwarz
Pharma as a 1 mg/ml solution. PGF2α (tromethamine
salt), from Cayman Chemicals, was prepared as a 100 mM
stock solution in dimethylsulphoxide. Phenylephrine
hydrochloride, serotonin creatinine sulphate and car-
bamylcholine chloride (carbachol) were from Sigma and
prepared as 10 mM stock solutions in distilled water. Aliq-
uots of each stock solution were stored frozen and diluted
in PSS as required.
Results
The control rats had a mean body weight of 355 ± 9 g and
blood glucose of 82 ± 6 mg/dl (n = 23). The diabetic rats
had significantly lower body weight (266 ± 5 g, p <
0.0001) and higher blood glucose levels (319 ± 35 mg/dl,
p < 0.0001) than the age-matched control animals.
Depolarisation induced vasoconstriction
Elevation of the extracellular K+ concentration causes con-
striction of pulmonary arteries due to depolarisation of
the smooth muscle membrane [17] and voltage-gated
Ca2+ influx. Figure 1 compares the concentration depend-
ence of K+-induced constriction of conduit (A) and resist-
ance (B) intrapulmonary arteries from STZ-treated rats
and age-matched controls. STZ-induced diabetes had little
effect on the concentration-response curve to K+ in small
or large vessels. The maximum response of conduit arter-
ies was observed above 50 mM K+, with 50% of the maxi-
mum seen at 42 ± 8 mM (n = 8) in control vessels and 36
± 4 mM (n = 10) in vessels from STZ-treated rats, with no
significant difference between these values. The K+ con-
centration-response relationship in resistance arteries
reached a maximum between 50 and 70 mM K+ and
declined at higher concentrations. A similar maximum
constriction was seen in the small vessels from control
and STZ-treated animals, amounting to 164 ± 18% (n = 9)
and 151 ± 12% (n = 8) of the response to 110 mM K+,
respectively. The K+ concentration producing a half maxi-
mal response was also similar in resistance vessels from
STZ-treated (30 ± 4 mM) and control (36 ± 5 mM) arter-
ies. These values were not significantly different from the
K+  concentrations producing 50% of the maximal
response in conduit vessels.
Responses to vasoconstrictor receptor agonists
The effects of three receptor agonists, widely used in phys-
iological studies of pulmonary artery, were investigated in
intrapulmonary arteries from control and STZ-treated rats.
Phenylephrine, an α1-adrenoceptor agonist, serotonin
and prostaglandin F2α (PGF2α) all produced concentra-
tion-dependent constriction of conduit and resistance ves-
sels from control and diabetic animals (Figure 2). The
concentration-response curves for phenylephrine dis-
played a peak at 1 μM, waning at higher concentrations
(Figure 2A). We did not investigate the falling phase fur-
ther and responses to the highest concentrations of ago-
nist were ignored when fitting the Hill equation to
estimate the maximum response and pEC50 values for
each tissue.
As previously reported [18], resistance vessels were signif-
icantly less responsive to phenylephrine than conduit ves-
sels. While all of the conduit vessels tested from control
animals showed a robust response to phenylephrine, sev-
eral resistance vessels displayed either little or no
response. The mean maximum constriction measured in
control conduit vessels, at 84 ± 9% (n = 12) of the
response to 50 mM KCl, was significantly larger than that
measured in control resistance arteries (33 ± 8%, n = 13,
p < 0.001). There was a similar difference between the
maximum responses to phenylephrine measured in con-
duit (57 ± 8%, n = 12) and resistance (21 ± 6%, n = 13, p
< 0.01) vessels from STZ-treated animals. From Figure 2A
it can be seen that STZ treatment resulted in a loss of phe-
nylephrine efficacy, with the maximum response of con-
duit vessels 32% smaller (p < 0.05) in the STZ-treated
animals. Resistance vessels from STZ-treated rats appearedCardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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to show a 36% smaller maximum response relative to the
age-matched controls, but this difference did not reach
statistical significance. In contrast to the effect of STZ-
induced diabetes on the maximum response to phenyle-
phrine, it had no effect on the pEC50, which was the same
in all vessels: 7.4 ± 0.2 (n = 12) in control conduit arteries,
7.5 ± 0.2 (n = 11) in STZ-treated conduit arteries, 7.5 ± 0.2
(n = 13) in control resistance vessels and 7.2 ± 0.2 (n = 12)
in STZ-treated resistance arteries.
Resistance arteries from control animals were also less
sensitive to serotonin than conduit arteries from the same
animals (Figure 2B), with maximum responses amount-
ing to 85 ± 10% (n = 12) of the KCl constriction in con-
duit vessels and 56 ± 9% (n = 12, p < 0.05) in resistance
arteries. This differential effect disappeared in vessels from
STZ-treated rats, where serotonin produced a maximum
response of 46 ± 7% (n = 12) in conduit arteries and 51 ±
7% (n = 12) in resistance vessels. These results indicate
that in STZ-induced diabetes, conduit vessels experienced
a 46% (p < 0.01) reduction in the maximum response to
serotonin while the response of resistance vessels was
essentially unchanged, with the measured 9% reduction
failing to reach statistical significance. The pEC50 values
for serotonin-induced constriction were similar in con-
duit arteries from control (5.8 ± 0.2, n = 12) and STZ-
treated (5.6 ± 0.2, n = 12) animals and in resistance arter-
ies from control (5.55 ± 0.08, n = 12) and STZ-treated (5.4
± 0.2, n = 12) animals.
In contrast to the results with phenylephrine and serot-
onin, conduit and resistance arteries showed a similar sen-
sitivity to PGF2α-induced vasoconstriction (Figure 2C). A
maximum response was not always reached at the highest
concentration of PGF2α tested. Nevertheless, at 10 μM
PGF2α, which appeared to produce a near maximum con-
Resistance of depolarisation-induced pulmonary artery constriction to STZ-induced diabetes Figure 1
Resistance of depolarisation-induced pulmonary artery constriction to STZ-induced diabetes. Constrictor 
responses to increasing concentrations of extracellular K+, measured as a percentage of the response to 110 mM K+, in con-
duit (A) and resistance-sized (B) intrapulmonary arteries from STZ-treated (solid circles) and age-matched control (open cir-
cles) rats. Data plotted are mean ± s.e.m. of 8–10 animals.Cardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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traction, there was no significant difference between the
responses evoked in conduit (86 ± 16%, n = 6) or resist-
ance (89 ± 18%, n = 7) arteries from control animals. The
responses of conduit (53 ± 13%, n = 5) and resistance
arteries (46 ± 15%, n = 5) from STZ-treated animals to 10
μM PGF2α were also not significantly different. Further-
more, STZ had little effect on the sensitivity of intrapul-
monary arteries to PGF2α. Although responses to 10 μM
PGF2α appeared smaller in conduit (38%) and resistance
(48%) arteries from animals treated with STZ compared
with the age-matched controls, these differences were not
statistically significant. Estimates of pEC50 were also not
significantly different between control (conduit 5.5 ± 0.2,
n = 8; resistance 5.57 ± 0.05, n = 7) and STZ-treated (con-
duit 5.59 ± 0.07, n = 5; resistance 5.66 ± 0.08, n = 7) ani-
mals.
Responses to vasodilator drugs
Conduit and resistance arteries from control and STZ-
treated animals displayed a robust response to the
endothelium-dependent vasodilator, carbachol (Figure
3), indicating that the integrity of the endothelium was
well preserved during vessel preparation even in the small
arteries. The dilator effect of carbachol, measured relative
Effect of STZ-induced diabetes on responses to vasoconstrictor agonists Figure 2
Effect of STZ-induced diabetes on responses to vasoconstrictor agonists. Concentration response curves for vaso-
constriction evoked by phenylephrine (A), serotonin (B) and PGF2α (C) in conduit (upper panels) and resistance (lower panels) 
arteries. Responses were measured as a percentage of the constriction induced by 50 mM KCl and are shown for STZ-treated, 
diabetic (solid circles) and age-matched control rats. Data plotted are mean ± s.e.m. with n = 12–13 (phenylephrine), n = 12 
(serotonin) or n = 3–10 (PGF2α). *P < 0.05, ***P < 0.001 versus control.Cardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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to the constrictor tone present before its application, was
however smaller in resistance arteries compared with con-
duit vessels. The vessels from control animals responded
with a maximum dilation of 75 ± 8% (n = 9) in conduit
arteries and 44 ± 15% (n = 9, p = 0.05) in resistance arter-
ies. Vessels from STZ-treated, diabetic animals showed a
similar difference, conduit arteries responding with a
maximum relaxation of 88 ± 9% (n = 9) compared with
46 ± 10% (n = 9, p < 0.05) in resistance arteries. It is
apparent from Figure 3 that there was no effect of STZ on
the responses to carbachol, the maximum responses being
similar in the equivalent vessels from STZ-treated and age-
matched control animals. Similar pEC50 values for carba-
chol induced vasodilation were found in conduit arteries
from control (7.0 ± 0.2, n = 9) and STZ-treated (6.7 ± 0.2,
n = 9) animals and in resistance arteries from control (6.8
± 0.4, n = 8) and STZ-treated (6.9 ± 0.4, n = 7) animals.
Glyceryl trinitrate (GTN) was used as an example of a
directly acting vasodilator, which releases nitric oxide in
pulmonary artery smooth muscle cells to activate cGMP-
dependent relaxation [19]. Conduit and resistance pul-
monary arteries appeared to be equally sensitive to GTN,
which evoked dilation with similar potency in all arteries,
whether isolated from control or STZ-treated animals
(Figure 4). In vessels from control animals, the maximum
vasodilator response to GTN, measured relative to the
constrictor tone present before its application, was 72 ±
6% (n = 8) in conduit arteries and 80 ± 8% (n = 9) in
resistance arteries. The maximum dilation response
induced by GTN in vessels from STZ-treated animals was
83 ± 3% (n = 8) in conduit arteries and 86 ± 21% (n = 7)
in resistance arteries. The pEC50  values for the GTN-
induced dilation of conduit vessels were 6.7 ± 0.3 (n = 8)
for control animals and 6.6 ± 0.3 (n = 8) for STZ-treated
Resistance of endothelium-dependent vasodilation to STZ-induced diabetes Figure 3
Resistance of endothelium-dependent vasodilation to STZ-induced diabetes. Dilator responses to increasing con-
centrations of carbachol, measured as a percentage of pre-constrictor tone, in conduit (A) and resistance-sized (B) intrapulmo-
nary arteries from STZ-treated (solid circles) and age-matched control (open circles) rats. Data plotted are mean ± s.e.m. of 
9–11 animals.Cardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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diabetic animals. Similar pEC50 values were obtained in
resistance arteries, with 6.6 ± 0.5 (n = 9) found for control
animals and 7.3 ± 0.5 (n = 7) for STZ-treated diabetic ani-
mals. In the studies on GTN action there were no signifi-
cant differences found between any of the measurements
of pEC50 or maximum response.
Discussion
The results imply that rat small intrapulmonary arteries
are relatively resistant to diabetes, even 3–4 months after
induction by STZ. Depolarisation-induced vasoconstric-
tion was well maintained in both conduit and resistance
intrapulmonary arteries. Agonist induced vasoconstric-
tion was not significantly altered by diabetes in resistance
arteries, but it was blunted in conduit vessels. There are
several reasons to believe that this effect was due to hyper-
glycaemia rather than a direct action of STZ. Firstly, loss of
the pulmonary pressor response to agonist in the salt-per-
fused lung of STZ diabetic rats was prevented by intensive
insulin therapy [11,20]. In addition, PAs from rats treated
with a higher dose of STZ and studied 6 weeks after expo-
sure did not display a loss of responsiveness to phenyle-
phrine [12]. Surprisingly, endothelium-dependent
vasodilation as well as endothelium-independent vasodi-
lation appeared normal in the 3–4 month diabetic ani-
mals. Thus there was no evidence for endothelial
dysfunction in the pulmonary arteries of diabetic rats in
this study.
Another study recently examined the effects of STZ-
induced diabetes on isolated rat pulmonary arteries, with
differing results. Lopez-Lopez and colleagues found that
Resistance of endothelium-independent vasodilation to STZ-induced diabetes Figure 4
Resistance of endothelium-independent vasodilation to STZ-induced diabetes. Dilator responses to increasing con-
centrations of glyceryl trinitrate (GTN), measured as a percentage of pre-constrictor tone, in conduit (A) and resistance-sized 
(B) intrapulmonary arteries from STZ-treated (solid circles) and age-matched control (open circles) rats. Data plotted are 
mean ± s.e.m. of 8–9 animals.Cardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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STZ treatment enhanced the constrictor response to phe-
nylephrine, while reducing the endothelium-dependent
relaxation to acetylcholine [12]. There are several possible
reasons for the discrepancies. Firstly the latter study
employed larger arteries (0.5–0.8 mm) than used here
and our results suggest that larger pulmonary arteries are
more sensitive to the effects of diabetes. It also used
smaller rats and a larger dose of STZ, which may have
resulted in more severe hyperglycaemia [8]. This is further
suggested by the criterion for hyperglycaemia (>350 mg/
dL), which was higher than applied here, although mean
blood glucose levels were not reported. On the other
hand, arteries were examined after only 6 weeks of diabe-
tes compared with 3–4 months here. Since the effects of
diabetes on the systemic vasculature are known to change
over time [6,21] it is possible that an early loss of endothe-
lium-dependent vasodilation in the pulmonary circula-
tion is compensated for later in the disease.
Vasoconstriction
Conduit and resistance pulmonary arteries showed dis-
tinct K+ concentration-response relationships, the maxi-
mum contractile force being maintained at high K+
concentrations in conduit but not resistance arteries. The
drop off in the response of small vessels at high K+ concen-
trations is likely to reflect cellular events downstream of
membrane depolarisation, because the smooth muscle
membrane potentials in small and large pulmonary arter-
ies show a similar dependence on K+ concentration [22].
Whatever the reason for the different sensitivities of con-
duit and resistance vessels to K+, the relationships were
unaffected by STZ-induced diabetes, implying that depo-
larisation-induced Ca2+ entry and the pathways linking
the rise in smooth muscle Ca2+ concentration to contrac-
tion were well maintained in this model of diabetes.
Conduit arteries displayed a 61% larger maximum
response to phenylephrine and a 34% larger maximum
response to serotonin compared with resistance vessels,
consistent with previous studies on similar sized pulmo-
nary arteries [18,23]. The differential effect of serotonin
disappeared in the STZ diabetic rats, apparently due to a
greater loss of responsiveness in the conduit than resist-
ance arteries. The conduit arteries from diabetic rats also
displayed a significant loss of responsiveness to phenyle-
phrine. The maximum response of resistance arteries to
phenylephrine was 64% smaller than in the conduit ves-
sels, but was not significantly altered in diabetes. Thus it
appears that diabetes preferentially blunts responsiveness
to agonist-induced constriction in the conduit vessels. A
similar impairment of phenylephrine and serotonin
induced constriction was seen in aortae from rats experi-
encing a similar duration of STZ-induced diabetes [24],
although other studies found the phenylephrine sensitiv-
ity of aorta to be unchanged or enhanced [e.g. [15,25]].
In contrast to our findings with phenylephrine and serot-
onin, but consistent with a previous report [18], PGF2α
produced similar constrictor responses in conduit and
resistance pulmonary arteries. Moreover, the responses in
both vessels were not significantly affected by STZ diabe-
tes. The effect of chronic diabetes on vasoconstrictor
responses was therefore agonist dependent, the order of
sensitivity being serotonin > phenylephrine > PGF2α, and
it was largely restricted to the conduit pulmonary arteries.
Although the agonist responsiveness of resistance arteries
was not significantly altered in diabetic rats, the maxi-
mum constriction to all three agents tested did show a
trend towards a decrease. Perhaps this reflects the early
stages of changes in vascular reactivity that might become
significant in more severe or prolonged diabetes. The ago-
nist dependence of the deficit in conduit arteries suggests
that it reflects loss of receptors or reduced receptor respon-
siveness, rather than altered downstream pathways. Since
diabetes did not affect the pEC50 values of any agonist, it
seems likely that there is altered receptor activity without
a change in the molecular makeup of the receptors. Fur-
ther experiments, such as measurements of receptor bind-
ing and evoked changes in cytoplasmic Ca2+
concentration, will be required to determine the underly-
ing mechanism.
The comparatively greater effect of diabetes on serotonin-
induced vasoconstriction is interesting in view of evidence
linking enhanced serotonergic activity, both at serotonin
receptors and the serotonin transporter, to pulmonary
hypertension [26,27]. Serum serotonin concentrations are
elevated in diabetics [28] and there is evidence for up reg-
ulation of the serotonin transporter in platelets [29] and
brain [30]. These effects may well contribute to the
increased prevalence of pulmonary hypertension in dia-
betics, because over expression of the serotonin trans-
porter in mice causes pulmonary hypertension [31]. The
loss of responsiveness of pulmonary arteries to serotonin
in diabetes would have the opposite effect. So perhaps this
change reflects a compensatory mechanism, which arises
to counteract the increased activity of peripheral serotonin
pathways and protect against the development of pulmo-
nary vasoconstriction.
Vasodilation
The STZ diabetic rats in this study displayed normal
endothelium-dependent dilation to carbachol in both
conduit and resistance pulmonary arteries. This contrasts
with many studies reporting impaired endothelium-
dependent dilation in systemic arteries. There are, how-
ever, mixed reports from studies examining endothelium-
dependent dilation of aorta after 3 months of STZ-
induced diabetes. While impaired responses have been
reported [24], others found no effect on the endothelium
[25,32], a longer period of diabetes (52 weeks) beingCardiovascular Diabetology 2009, 8:4 http://www.cardiab.com/content/8/1/4
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required to produce a deficit [25]. On the other hand, loss
of endothelium-dependent vasodilation has been
reported in rat aorta following shorter periods of diabetes
[6,33,34] and as early as 2 weeks after STZ treatment
[35,36]. Similar disparities can be found among studies
on renal [37], mesenteric [38] and coronary [39] arteries.
The reasons for these discrepancies are not clear, but could
be related to the dose of STZ administered and/or the age
and gender of the rats used, as all of these factors affect the
severity and time course of hyperglycaemia [8].
Although there are inconsistencies in the literature con-
cerning the effects of STZ-induced diabetes on responses
of systemic arteries to vasoconstrictors and endothelium-
dependent vasodilators, there seems to be widespread
agreement that STZ treatment does not affect responses to
vasodilators that act directly on smooth muscle, such as
GTN and sodium nitroprusside. The effect of GTN on pul-
monary arteries was also unaffected by chronic diabetes.
Thus enhanced dilator potency of nitric oxide, released
constitutively from the endothelium, cannot explain the
loss of responsiveness to phenylephrine and serotonin in
pulmonary arteries from diabetic rats.
Conclusion
The results of this study suggest that small resistance pul-
monary arteries are relatively resistant to STZ-induced dia-
betes. While conduit arteries showed a loss of
responsiveness to serotonin and phenyephrine in chronic
diabetes, no significant change was seen in resistance
arteries. Diabetes had a differential effect on the constric-
tor responses to different receptor agonists, with serot-
onin affected more than phenylephrine and PGF2α
constriction unchanged, suggesting that there may be dif-
ferentially altered expression or function of receptors. The
loss of agonist responses may represent a compensatory
mechanism to protect the pulmonary circulation from
changes in diabetes that promote pulmonary vasocon-
striction. In this study, chronic diabetes had no effect on
endothelium-dependent or endothelium-independent
vasodilation, but an effect on the endothelium cannot be
ruled out as a recent study, carried out under different
conditions, did find reduced endothelium-dependent
vasodilatation in conduit pulmonary arteries.
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